At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 50 enrolled
Drug / intervention
AMG 598 +2 moredrug
Likely dose
Liraglutide 0.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With Obesity
In Brief
A Phase 1 clinical trial evaluating AMG 598, Placebo, and 1 other intervention for Obesity. Completed, enrolled 50 participants across 4 sites.
Detailed Summary
The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedNov 2018
Primary CompletionDec 2019
TodayJul 2026
First PostedNov 28, 2018
Enrollment StartNov 26, 2018
Primary CompletionDec 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.6 years ago
Interventions
AMG 598drug
AMG 598 administered by subcutaneous injection
Placebodrug
Placebo matching to AMG 598 administered by subcutaneous injection
Liraglutidedrug
Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.